Galiximab

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.^[1] As of September 2009^[update], it is undergoing Phase III clinical trials.^[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.^[3]

Galiximab

Monoclonal antibody
Type	Whole antibody
Source	Chimeric (primate/human)
Target	CD80
Clinical data
ATC code	none
Identifiers
CAS Number	357613-77-5 N
ChemSpider	none
UNII	S9OX9692ZB
KEGG	D04295 Y
NY (what is this?)  (verify)